share_log

Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1020

Benzinga ·  Jan 23 08:21

Barclays analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $935 to $1020.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment